An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
about
Intravesical bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancerThe Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder CancerHigh-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG ShortageHow do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and ProgressionComparison of Guidelines on Non-Muscle Invasive Bladder Cancer (EAU, CUA, AUA, NCCN, NICE)Bacille-Calmette-Guerin non-responders: how to manageIntravesical chemotherapy in non-muscle-invasive bladder cancerApplications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapyCurrent perspectives in bladder cancer managementDefining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancerBacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccineBacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive DiseaseImmunotherapy in urothelial carcinoma: fade or future standard?Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).Identification of S100A8-correlated genes for prediction of disease progression in non-muscle invasive bladder cancerLong-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and highSWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-GuérinThermal dosimetry characteristics of deep regional heating of non-muscle invasive bladder cancer.Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium.Update on intravesical agents for non-muscle-invasive bladder cancerMagnetic fluid hyperthermia for bladder cancer: a preclinical dosimetry study.Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review.Sequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trialIs intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.Therapeutic effect of intravesical administration of paclitaxel solubilized with poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate) in an orthotopic bladder cancer model.Best practice in the treatment of nonmuscle invasive bladder cancer.Antitumor effects of human interferon-alpha 2b secreted by recombinant bacillus Calmette-Guérin vaccine on bladder cancer cells.Surveillance and treatment of non-muscle-invasive bladder cancer in the USA.Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune responseEnhanced antitumor effect of combination intravesical mitomycin C and bacillus Calmette-Guerin therapy in an orthotopic bladder cancer model.Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations.Myobacterium bovis peri-prosthetic hip infection with successful prosthesis retention following intravesical BCG therapy for bladder carcinomaA prospective comparison of intra-arterial chemotherapy combined with intravesical chemotherapy and intravesical chemotherapy alone after transurethral resection with a thulium laser in high-risk non-muscle invasive bladder cancer.Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis.Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non-Muscle-Invasive Bladder CancerAggressive muscle-invasive bladder cancer with sarcomatoid differentiation in a 10-year-old girl: A case report.Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerManagement of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?Immunotherapy for urothelial carcinoma: current status and perspectives.
P2860
Q24188295-0E6A5DCE-2E9C-4B15-BEC0-E20226863D87Q26738516-CEDF1340-BFC8-43A9-8B82-46111404B2A6Q26739003-CCDE1C48-11CF-40EC-BC77-DC2721CF0514Q26744155-42D1EBA3-BA22-4399-A7DF-55995DD60C9BQ26744754-456BF9A6-E21A-4AFB-8940-7FF108711915Q26744756-98338104-F4CC-4F87-8A0A-F5BE1B490EC7Q26773679-0D1691CD-FC26-4388-98E6-E256728FC0CFQ26775982-AB061473-AA59-4BA6-BA5A-CAFE5E9E20D8Q26798372-7D91AC4B-DCBD-4246-91FD-26E878C6E3A4Q26824914-3A446EAE-FC3E-4218-B6DE-24CBBF5B3328Q26852084-3A2EBE60-0726-437A-98A0-B66A33529CF4Q27006765-7CE48088-E4DD-41AB-BD23-79C1A47A426AQ27011829-42C92B54-2231-42C2-85E6-0898372E627AQ28078284-1D7C5FD3-1F24-42CF-8C07-2C5A253727EFQ30596342-A37FAE23-2ECC-477E-9CC2-08B7AFE5237CQ33526078-CA6AF5DF-D903-4458-818A-7C7F934A86F3Q33927694-30F608BD-26F7-4E71-9A09-D943E49F6B16Q33962426-E7CF68CE-4F86-494E-99CF-3548107E3A18Q34147801-9ABBC924-51DE-46DE-AEA3-D7E1BAF37E9EQ34205117-4EBC1FCE-C380-4746-9EE8-FA3256C22802Q34584575-62BF67CC-06FB-4C9B-A667-614B2846883EQ34667806-10601BE5-AF47-4E96-8057-2AC19FE82307Q34751946-88A8D85C-D950-46AD-A151-FAED400A70ACQ34979760-56CB7260-7033-4BB1-B363-6DE07C7014F7Q35089307-3526BBBB-CE96-44F5-9C0A-388FE2394C7DQ35588309-FF0A098E-CE27-4324-859F-6E7399C18303Q35688392-B5440E29-ECCD-4DCD-8834-A01576E1C864Q35946382-0B4A343E-F165-406E-9AD3-40D17D62C821Q35977496-B441B26D-8C48-40AE-B096-E536A72B93CFQ36038379-6B0AC908-930C-4F3D-98B3-65046266C155Q36142577-F2E8B003-86C2-4D46-A4E8-4C77E84A6E72Q36187495-E7353FCA-A44E-479E-9AE5-59AA4E6B6819Q36276438-CDBD407A-0B0F-4985-99F2-7C7600DC149BQ36350505-264D6DD9-C79B-4015-A04C-85B0DA438D4EQ36362803-7CA17F05-06D2-43DC-A82B-25500EC99DE2Q36397311-163ADA41-5C8F-4A0B-8BC5-8A4A9ED7BADCQ36640085-A5396DF5-2661-462F-9732-3EE04F9E8250Q37053820-092AAD4B-E0B6-4206-98D6-F401168E2008Q37053829-B7C303FF-3211-4D74-B135-F39A784A265AQ37137381-8460F5B1-AA32-4882-A937-43700FA1D3A7
P2860
An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
An individual patient data met ...... uscle-invasive bladder cancer.
@ast
An individual patient data met ...... uscle-invasive bladder cancer.
@en
type
label
An individual patient data met ...... uscle-invasive bladder cancer.
@ast
An individual patient data met ...... uscle-invasive bladder cancer.
@en
prefLabel
An individual patient data met ...... uscle-invasive bladder cancer.
@ast
An individual patient data met ...... uscle-invasive bladder cancer.
@en
P2093
P1433
P1476
An individual patient data met ...... uscle-invasive bladder cancer.
@en
P2093
David E Crawford
Eduardo Solsona
Erkki Rintala
J Alfred Witjes
Martin Friedrich
Richard J Sylvester
Savino M Di Stasi
Susanne Krege
P304
P356
10.1016/J.EURURO.2009.04.038
P407
P577
2009-04-24T00:00:00Z